Categories
Resources
Your Recalls
Loading...
Get email alerts when new recalls match your interests.
Due to different color of powder in capsules. Firm's evaluation determined product low potency.
Lack of Assurance of Sterility
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level
Failed impurities/degradation specification: Out-of-Specification result for total impurity at 4.1% (Limit: NMT 3.0%) during retained sample testing.
CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.
CGMP Deviations: These products have been found to be misbranded as unapproved new drugs